HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ray, J. Articles by Liebhaber, S. A. Search for Related Content PubMed PubMed Citation Articles by Ray, J. Articles by Liebhaber, S. A. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 265, Issue 14, 7939-7944, 05, 1990

Human growth hormone-variant demonstrates a receptor binding profile distinct from that of normal pituitary growth hormone

J Ray, H Okamura, PA Kelly, NE Cooke and SA Liebhaber
Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia 19104-6145.

We have recently established that the human growth hormone-variant (hGH- V) gene is functional in vivo by documenting its expression in the placenta. We have subsequently generated transformed murine cell lines stably expressing the genes for normal pituitary growth hormone (hGH- N), hGH-V, and each of two chimeric genes generated by exon 3 exchanges, hGH-NV3 and hGH-VN3. In the present study, we utilize these cell lines as sources of hormone to characterize and compare the receptor binding profiles of hGH-N with hGH-V. hGH-V was found to displace 125I-ovine prolactin bound to rat liver microsomes (lactogen binding) and to displace 125I-hGH bound to rabbit liver microsomes (somatogen binding). Therefore, hGH-V would be predicted to display both somatogenic and lactogenic bioactivity, a dual specificity previously thought to be unique to hGH-N. The concentrations of hormone necessary to displace 50% (IC50) of the 125I-hGH from somatogen receptors and 125I-ovine prolactin from lactogen receptors was expressed as a ratio, IC50 somatogen: IC50 lactogen, for each hormone tested. A 7.4-fold difference in this ratio was observed for hGH-N compared to hGH-V, suggesting significantly greater selectivity by hGH- V in binding to the somatogen receptor. The intermediate binding ratios of the hGH-NV3 and hGH-VN3 chimeric proteins confirmed the distinct receptor binding profiles of the two parent hormones and served to identify three amino acids of potential importance in defining their respective receptor binding specificities.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z. Wu, M. Bidlingmaier, S. C. Friess, S. E. Kirk, P. Buchinger, B. Schiessl, and C. J. Strasburger A New Nonisotopic, Highly Sensitive Assay for the Measurement of Human Placental Growth Hormone: Development and Clinical Implications J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 804 - 811. [Abstract] [Full Text] [PDF]

				F. Dif, E. Saunier, B. Demeneix, P. A. Kelly, and M. Edery Cytokine-Inducible SH2-Containing Protein Suppresses PRL Signaling by Binding the PRL Receptor Endocrinology, December 1, 2001; 142(12): 5286 - 5293. [Abstract] [Full Text] [PDF]

				B. Cunningham, S Bass, G Fuh, and J. Wells Zinc mediation of the binding of human growth hormone to the human prolactin receptor Science, December 21, 1990; 250(4988): 1709 - 1712. [Abstract] [PDF]